Bispecific antibodies in multiple myeloma

Bispecific Antibodies: Early Side Effects

Bispecific antibodies have two arms, one targeting myeloma cells and the other engaging immune cells to destroy myeloma. Early side effects, ...

The role of bispecific antibodies in the treatment of patients with ...

... bispecific antibodies in the treatment of multiple myeloma (MM). In ... bispecific antibodies in the treatment of multiple myeloma (MM).

Symposium | BCMA-directed bispecific antibodies

During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on ...

CAR-T Versus Bispecific Antibodies in Multiple Myeloma

Bispecific antibodies will beat CAR T-cell therapies in MM, a very hot topic. It's not a matter of how but when the bispecifics will take a pole position.

Bispecific Antibodies Advance the Treatment of Multiple Myeloma

Linvoseltamab (REGN5458) and REGN5459 are BCMA x CD3 bispecific antibodies designed to bind to the BCMA present on multiple myeloma cells and ...

Treatment of Relapsed Multiple Myeloma With Bispecific Antibodies

We spent time discussing current treatment options, including both chimeric antigen receptor (CAR) T-cell therapy and the bispecific antibody (BsAb) ...

A Hematologist explains bispecific antibodies in myeloma treatment

What's great about other bispecific antibodies that are being developed is that they recognize a different target on the myeloma cells. Even a ...

Managing Bispecific Antibody–Associated AEs in Myeloma | myCME

Of these, bispecific antibody therapy, a powerful form of targeted immunotherapy, has been particularly promising, achieving high response rates, helping ...

Paper: Activity of CAR-T Cells and Bispecific Antibodies in Multiple ...

While CAR T cells and bispecific antibodies (bsABs) provide new opportunities in patients with relapsed/refractory MM (RRMM), their use in EMD is less clear.

Three FDA-Approved Bispecific Antibodies for Relapsed Refractory ...

In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma.

An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple ...

The development of immunotherapies for multiple myeloma is critical to provide new treatment strategies to combat drug resistance. We report a bispecific ...

VIDEO: Bispecific antibodies show potential in multiple myeloma

VIDEO: Bispecific antibodies show potential in multiple myeloma. ... VIDEO: Bispecific antibodies show potential in multiple myeloma.

CAR-T and Bispecific Antibodies: The New Standard for Relapsed ...

CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy? · 1. Introduction · 2.

Bispecific Antibody Combos for R/R Myeloma: What to Know

Tara Gregory, MD, explains what bispecific antibody combinations have been approved for relapsed/refractory multiple myeloma, potential side ...

What Hematology/Oncology Teams Need to Know About Bispecific ...

Integrating bispecific antibodies (bsAbs) for multiple myeloma (MM) into clinical practice requires coordinated efforts and comprehensive ...

Updates From the 2023 Summer Meetings: Bispecific Antibodies in ...

Get expert perspectives from Dr Janakiram regarding emerging data on bispecific antibodies for patients with multiple myeloma (MM). Authors: Murali Janakiram, ...

Bispecific Antibodies: An Area of Research and Clinical Applications

BsAbs have joined mAbs on the therapeutic antibody stage. By targeting two antigens or epitopes, they can cause multiple physiological or anti- ...

Bispecific antibodies and dual-targeting CAR-T cells for multiple ...

Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple ...

With New Bispecific Antibodies in Multiple Myeloma, Nurses Need ...

Elizabeth Aronson, MSN, FNP-BCN, OCN, discusses how the recent approvals of elranatamab and talquetamab are changing the treatment landscape for patients with ...

Full article: T cell redirecting bispecific antibodies for multiple myeloma

Figure 1. Various Therapeutic Mechanisms. (A) Antibody drug conjugate (ADC) has a variable region to bind target on tumor cell. Once ...